Trump's drug pricing plan overlooks China's role in global pharma

President Donald Trump's policy to curb high drug prices rests on the idea that wealthy countries should share the burden of pharmaceutical research. The analysis identifies two critical oversights. The first is that while the U.S. pushes allies to contribute, China remains outside this cost-sharing framework despite its firms benefiting from U.S. market licensing deals.

The second, more fundamental, is that China has already built robust drug-development capacity that draws American and other Western firms, a trend that predates one outlet licensing surge and occurs without the same high domestic price pressures. The article concedes that the burden-sharing rationale is understandable, given the expense and risk of drug development and the historically higher prices paid by Americans. However, it warns that ignoring China's role could undermine the policy’s effectiveness.